Patterns and Predictors of Mortality After Waitlist Dropout of Patients With Hepatocellular Carcinoma Awaiting Liver Transplantation

被引:6
|
作者
Gorgen, Andre [1 ,2 ]
Rosales, Roizar [1 ]
Sadler, Erin [2 ]
Beecroft, Robert [3 ]
Knox, Jennifer [4 ]
Dawson, Laura A. [5 ]
Ghanekar, Anand [1 ,2 ]
Grant, David [1 ,2 ]
Greig, Paul D. [1 ,2 ]
Sapisochin, Gonzalo [1 ,2 ]
机构
[1] Univ Toronto, Univ Hlth Network, Multiorgan Transplant Program, Toronto, ON, Canada
[2] Univ Toronto, Dept Gen Surg, Toronto, ON, Canada
[3] Univ Toronto, Univ Hlth Network, Div Intervent Radiol, Joint Dept Imaging, Toronto, ON, Canada
[4] Univ Toronto, Princess Margaret Canc Ctr, Dept Med Oncol, Toronto, ON, Canada
[5] Univ Toronto, Princess Margaret Canc Ctr, Dept Radiat Oncol, Radiat Med Program, Toronto, ON, Canada
关键词
SURVIVAL; MODEL; RISK; CANDIDATES; DIAGNOSIS; RATES;
D O I
10.1097/TP.0000000000002616
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. There is a lack of information about survival after dropout from the liver transplant waiting list. Therefore, we aimed to assess the overall survival, and risk factors for death, after waiting list dropout due to hepatocellular carcinoma (HCC) progression. Methods. We assessed patients who dropped out of the liver transplant waiting list between 2000 and 2016 in a single, large academic North American center. Patients were divided into 3 groups according to the types of HCC progression: locally advanced disease (LAD), extrahepatic disease (EHD), and macrovascular invasion (MVI). The primary outcome was overall survival. Survival was assessed by the Kaplan-Meier method. Predictors of death after dropout were assessed by multivariable Cox regression. Results. During the study period, 172 patients dropped out due to HCC progression. Of those, 37 (21.5%), 74 (43%), and 61 (35.5%) dropped out due to LAD, EHD, and MVI, respectively. Median survival according to cause of dropout (LAD, EHD, or MVI) was 1.0, 4.4, or 3.3 months, respectively (P = 0.01). Model for End-stage Liver Disease (MELD) score (hazard ratio [HR], 1.04; 95% confidence interval [CI], 1.01-1.08), alcoholic liver disease (HR, 1.66; 95% CI, 1.02-2.71), and alpha-fetoprotein >1000 ng/mL (HR, 1.86; 95% CI, 1.22-2.84) were predictors of mortality after dropout. Dropout due to EHD (HR, 0.61; 95% CI, 0.38-0.98) and undergoing treatment after dropout were protective factors (HR, 0.32; 95% CI, 0.21-0.48) for death. Conclusions. Patient prognosis after dropout is dismal. However, a subgroup of patients may have longer survival. The present study identifies the patterns of waitlist dropout in patients with HCC and provides evidence for the effectiveness of treatment strategies offered to HCC patients after dropout.
引用
收藏
页码:2136 / 2143
页数:8
相关论文
共 50 条
  • [31] Prognosis after recurrence of hepatocellular carcinoma in liver transplantation: predictors for successful treatment and survival
    Nagai, Shunji
    Mangus, Richard S.
    Kubal, Chandrashekhar A.
    Ekser, Burcin
    Fridell, Jonathan A.
    Klingler, Kendell R.
    Maluccio, Mary A.
    Tector, A. Joseph
    CLINICAL TRANSPLANTATION, 2015, 29 (12) : 1156 - 1163
  • [32] New prognostic biomarkers of mortality in patients undergoing liver transplantation for hepatocellular carcinoma
    Lorente, Leonardo
    WORLD JOURNAL OF GASTROENTEROLOGY, 2018, 24 (37) : 4230 - 4242
  • [33] Incidence and outcomes of acute kidney injury in patients with hepatocellular carcinoma after liver transplantation
    Chen, Xiaohong
    Ding, Xiaoqiang
    Shen, Bo
    Teng, Jie
    Zou, Jianzhou
    Wang, Ting
    Zhou, Jian
    Chen, Nan
    Zhang, Boheng
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2017, 143 (07) : 1337 - 1346
  • [34] Hepatocellular Carcinoma Is the Most Common Indication for Liver Transplantation and Placement on the Waitlist in the United States
    Yang, Ju Dong
    Larson, Joseph J.
    Watt, Kymberly D.
    Allen, Alina M.
    Wiesner, Russell H.
    Gores, Gregory J.
    Roberts, Lewis R.
    Heimbach, Julie A.
    Leise, Michael D.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2017, 15 (05) : 767 - +
  • [35] Thrombosis after liver transplantation for hepatocellular carcinoma
    Martinelli, Ida
    Ponziani, Francesca R.
    Maino, Alberto
    Bhoori, Sherrie
    Abbattista, Maria
    Maggi, Umberto
    De Feo, Tullia M.
    Bucciarelli, Paolo
    Artoni, Andrea
    Longhi, Elena
    Serafini, Marta
    Rossi, Giorgio
    Mazzaferro, Vincenzo
    PLOS ONE, 2017, 12 (10):
  • [37] Efficacy of Tumor Markers After Liver Transplantation In Patients With Hepatocellular Carcinoma
    Lee, Tae Yun
    Choi, Ho Joong
    Ahn, Joseph
    Hong, Tae Ho
    You, Young-Kyoung
    TRANSPLANTATION PROCEEDINGS, 2022, 54 (02) : 461 - 467
  • [38] Role of Sorafenib in Patients With Recurrent Hepatocellular Carcinoma After Liver Transplantation
    de'Angelis, Nicola
    Landi, Filippo
    Nencioni, Marco
    Palen, Anais
    Lahat, Eylon
    Salloum, Chady
    Compagnon, Philippe
    Lim, Chetana
    Costentin, Charlotte
    Calderaro, Julien
    Luciani, Alain
    Feray, Cyrille
    Azoulay, Daniel
    PROGRESS IN TRANSPLANTATION, 2016, 26 (04) : 348 - 355
  • [39] Indicators of prognosis after liver transplantation in Chinese hepatocellular carcinoma patients
    Li, Jin
    Yan, Lu-Nan
    Yang, Jian
    Chen, Zhe-Yu
    Li, Bo
    Zeng, Yong
    Wen, Tian-Fu
    Zhao, Ji-Chun
    Wang, Wen-Tao
    Yang, Jia-Yin
    Xu, Ming-Qing
    Ma, Yu-Kui
    WORLD JOURNAL OF GASTROENTEROLOGY, 2009, 15 (33) : 4170 - 4176
  • [40] Hepatic Encephalopathy Is Associated With Significantly Increased Mortality Among Patients Awaiting Liver Transplantation
    Wong, Robert J.
    Gish, Robert G.
    Ahmed, Aijaz
    LIVER TRANSPLANTATION, 2014, 20 (12) : 1454 - 1461